ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.

Maria Patrícia A Oliveira MonteiroDanielle S M Salheb OliveiraPatrícia R ManzineCarla M Crispim NascimentoAriene A Dos Santos OrlandiGrace A de Oliveira GomesFabiana Dos Santos OrlandiMarisa S ZazzettaHenrique Pott-JuniorMarcia Regina Cominetti

Published in: Alzheimer's research & therapy (2021)

Considering that ADAM10 increase in plasma is detected as soon as in mild cognitive impairment (MCI) patients, the results presented here may support the complementary clinical use of this biomarker, in addition to the classical AD biomarkers. Taken together, these results provide the first direct evidence that changes in ADAM10 plasma levels are predictors of cognitive worsening in older adults. Moreover, this work can shed light on the study of blood biomarkers for AD and contribute to the advancement of the area.

Keyphrases

mild cognitive impairment
cognitive decline
end stage renal disease
physical activity
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
multiple sclerosis
white matter
patient reported outcomes